Sotatercept

How it works

Benefits

Risks & contraindications

Evidence quality

Highlighted claims

• Sotatercept is an activin-signalling inhibitor and ligand trap targeting activins in the transforming growth factor-beta superfamily. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Prior pivotal sotatercept trials excluded patients with unrepaired CHD and Eisenmenger syndrome, leaving uncertainty in cyanotic and erythrocytotic patients. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Known safety concerns for sotatercept include haemoglobin elevation, thrombocytopenia, epistaxis, and telangiectasia. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• In non-CHD adult PAH trials, sotatercept improved exercise capacity, pulmonary vascular resistance, NT-proBNP, and WHO functional class. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Sotatercept may act beyond vasodilatation by counterbalancing pro-proliferative signalling involved in pulmonary vascular remodelling. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri